HRTX News and Press, Heron Therapeutics Inc. From 04/05/22

Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference PR Newswire SAN DIEGO , April 5, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of...

Heron has lost 60% of its value in less than a year, despite the company making some progress. Zynrelef's launch is slow but showing signs of improvement with some important inflection points. CINV franchise has also disappointed and HTX-019 in PONV is now the only likely growth d...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Small and midcap growth stocks are where the discounts are right now. The three stocks I mention today are currently cheap and offer fat put premiums. Mind your asset allocation, but selling these cash-secured puts could be a great way to scale into these growth positions. F...

Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® fr...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Health Canada has approved Heron Therapeutics' (NASDAQ:HRTX) Zynrelef (bupivacaine and meloxicam extended-release solution) for postoperative pain. The company said the approval is the first for an extended-release local anesthetic in the country. The approval is for for postoperative analges...

Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain PR Newswire - ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada - SAN DIEGO , March 17, 2022 ...

The following slide deck was published by Heron Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Heron Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation